Arcutis Biotherapeutics
$23.63
126
-$0.47-1.95% Thursday 20:00
Statistics
Day High
24.07
Day Low
23.2
52W High
31.77
52W Low
11.86
Volume
638,063
Avg. Volume
1,434,401
Mkt Cap
2.93B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19MayExpected
Expected EPS
-0.053762
Actual EPS
N/A
Financials
-4.29%Profit Margin
Unprofitable752.14MRevenue
-32.28MNet Income
Analyst Ratings
$34.00Average Price Target
The highest estimate is 36.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 83%
Hold 17%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ARQT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap385.18B
AMGEN
AMGN
Mkt Cap160.66B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Pfizer
PFE
Mkt Cap140.15B
GSK
GSK
Mkt Cap94.51B
Novartis
NVS
Mkt Cap237.61B
Merck
MRK
Mkt Cap214.76B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Journey Medical
DERM
Mkt Cap213.64M
About
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Show more...
CEO
Mr. Todd Franklin Watanabe M.A.
Employees
342
Country
US
ISIN
US03969K1088
Listings
0 Comments
Share your thoughts
FAQ
What is Arcutis Biotherapeutics stock price today?▼
The current price of ARQT is $23.63 USD — it has decreased by -1.95% in the past 24 hours. Watch Arcutis Biotherapeutics stock price performance more closely on the chart.
What is Arcutis Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arcutis Biotherapeutics stocks are traded under the ticker ARQT.
Is Arcutis Biotherapeutics stock price growing?▼
ARQT stock has risen by +11.36% compared to the previous week, the month change is a -1.42% fall, over the last year Arcutis Biotherapeutics has showed a +60.42% increase.
What is Arcutis Biotherapeutics market cap?▼
Today Arcutis Biotherapeutics has the market capitalization of 2.93B
When is the next Arcutis Biotherapeutics earnings date?▼
Arcutis Biotherapeutics is going to release the next earnings report on May 19, 2026.
What were Arcutis Biotherapeutics earnings last quarter?▼
ARQT earnings for the last quarter are 0.13 USD per share, whereas the estimation was 0.09 USD resulting in a +40.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arcutis Biotherapeutics revenue for the last year?▼
Arcutis Biotherapeutics revenue for the last year amounts to 752.14M USD.
What is Arcutis Biotherapeutics net income for the last year?▼
ARQT net income for the last year is -32.28M USD.
How many employees does Arcutis Biotherapeutics have?▼
As of April 05, 2026, the company has 342 employees.
In which sector is Arcutis Biotherapeutics located?▼
Arcutis Biotherapeutics operates in the Health Care sector.
When did Arcutis Biotherapeutics complete a stock split?▼
Arcutis Biotherapeutics has not had any recent stock splits.
Where is Arcutis Biotherapeutics headquartered?▼
Arcutis Biotherapeutics is headquartered in Westlake Village, US.